Clinical Trials Logo

Clinical Trial Summary

The aim of Study BP41660 is to quantify the amount and concentration of [89Zr]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and [89Zr]DFO-RO7248824 administered via IT injection to healthy participants.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04863794
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: BP41660
Phone 888-662-6728
Email [email protected]
Status Recruiting
Phase Phase 1
Start date April 29, 2021
Completion date January 5, 2022

See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Not yet recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Completed NCT02996305 - A Study in Adults and Adolescents With Angelman Syndrome Phase 2
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3
Completed NCT00829439 - Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome Phase 1
Recruiting NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 2
Active, not recruiting NCT04259281 - A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome Phase 1/Phase 2
Completed NCT00296764 - Characterization of Angelman Syndrome
Active, not recruiting NCT03650569 - Angelman Syndrome Italian Registry
Recruiting NCT04103333 - Angelman Syndrome (AS) Biomarker Study Early Phase 1
Recruiting NCT04428281 - A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome Phase 1
Recruiting NCT04507997 - Angelman Syndrome Natural History Study
Completed NCT03109756 - Single Dose Pharmacokinetic (PK) Study Phase 1
Completed NCT02381457 - SNP-based Microdeletion and Aneuploidy RegisTry (SMART)